NASDAQ:SPRB Spruce Biosciences Q1 2024 Earnings Report $0.12 0.00 (-3.50%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.12 0.00 (-3.12%) As of 04/17/2025 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Spruce Biosciences EPS ResultsActual EPS-$0.28Consensus EPS -$0.32Beat/MissBeat by +$0.04One Year Ago EPSN/ASpruce Biosciences Revenue ResultsActual Revenue$2.00 millionExpected Revenue$1.12 millionBeat/MissBeat by +$880.00 thousandYoY Revenue GrowthN/ASpruce Biosciences Announcement DetailsQuarterQ1 2024Date5/13/2024TimeN/AConference Call DateMonday, May 13, 2024Conference Call Time4:00PM ETUpcoming EarningsSpruce Biosciences' next earnings date is estimated for Monday, May 12, 2025, based on past reporting schedules. Conference Call ResourcesSlide DeckPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Spruce Biosciences Earnings HeadlinesSpruce Biosciences (SPRB) Receives a Hold from RBC CapitalApril 17 at 6:08 PM | markets.businessinsider.comSpruce Biosciences, Inc. (NASDAQ:SPRB) Q1 2023 Earnings Call TranscriptApril 17 at 8:18 AM | insidermonkey.comTrump’s Top Secret $9 Trillion AI SuperweaponJeff Brown spotted Nvidia at $1. Now he’s revealing a new AI superweapon — and the Musk-connected stocks that could benefit.April 18, 2025 | Brownstone Research (Ad)With BioMarin deal, Spruce Biosciences hits reset on rare-disease drugApril 15 at 7:04 PM | bizjournals.comSpruce Biosciences, Inc. (SPRB) Corporate Update Conference Call (Transcript)April 15 at 6:01 PM | seekingalpha.comSpruce Biosciences reports delayed annual filingApril 3, 2025 | investing.comSee More Spruce Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Spruce Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spruce Biosciences and other key companies, straight to your email. Email Address About Spruce BiosciencesSpruce Biosciences (NASDAQ:SPRB), a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.View Spruce Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Archer Aviation Unveils NYC Network Ahead of Key Earnings Report3 Reasons to Like the Look of Amazon Ahead of EarningsTesla Stock Eyes Breakout With Earnings on DeckJohnson & Johnson Earnings Were More Good Than Bad—Time to Buy? Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions Ahead Upcoming Earnings Tesla (4/22/2025)Intuitive Surgical (4/22/2025)Verizon Communications (4/22/2025)Canadian National Railway (4/22/2025)Novartis (4/22/2025)RTX (4/22/2025)3M (4/22/2025)Capital One Financial (4/22/2025)General Electric (4/22/2025)Danaher (4/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
